Effect of Pretransplant Rituximab Use on Posttransplant Clinical Outcomes in Patients with High Panel Reactive Antibody Scores

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nephron

• Publication date

  2015-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000435924PMID 26182858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peak Panel Reactive Antibody, Cancer, Graft, and Patient Outcomes in Kidney Transplant Recipients

  2015cited by this paper
• Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis

  2014cited by this paper
• A Systematic Review of the Use of Rituximab for Desensitization in Renal Transplantation

  2014cited by this paper
• Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab

  2013cited by this paper
• Combined use of rituximab and plasmapheresis pre‐transplant increases post‐transplant infections in renal transplant recipients with basiliximab induction therapy

  2013cited by this paper
• The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review

  2012cited by this paper
• Chronic Antibody‐Mediated Rejection Is Reduced by Targeting B‐Cell Immunity During an Introductory Period

  2012cited by this paper
• Treatment options and strategies for antibody mediated rejection after renal transplantation.

  2012cited by this paper
• Dysregulation of Th17 Cells during the Early Post-Transplant Period in Patients under Calcineurin Inhibitor Based Immunosuppression

  2012cited by this paper
• Desensitization of HLA-incompatible kidney recipients.

  2011cited by this paper
• Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.

  2011cited by this paper
• Incidence of Infectious Complications in Highly Sensitized Renal Transplant Recipients Treated by Rituximab: A Case-Controlled Study

  2010cited by this paper
• Sensitized renal transplant recipients: current protocols and future directions

  2010cited by this paper
• Donor-specific HLA class I and CREG antibodies in complement-dependent cytotoxicity-negative renal transplants.

  2010cited by this paper
• Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

  2010cited by this paper
• Utility of virtual crossmatch in sensitized patients awaiting heart transplantation.

  2009cited by this paper
• [Comparative evaluation of ELISA and Luminex panel reactive antibody assays for HLA alloantibody screening].

  2009cited by this paper
• A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

  2008cited by this paper
• Rituximab and intravenous immune globulin for desensitization during renal transplantation.

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions

  2008cited by this paper
• Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.

  2006cited by this paper
• Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

  2005cited by this paper
• Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.

  2005cited by this paper
• Predicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial

  2004cited by this paper
• Importance of peak PRA in predicting the kidney transplant survival in highly sensitized patients.

  2003cited by this paper
• Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

  1991cited by this paper

• Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies

  2026cites this paper
• Impact of sex on clinical outcomes according to immunologic risk in spousal donor kidney transplantation.

  2024cites this paper
• Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients

  2023cites this paper
• Kidney transplantation in highly sensitized recipients

  2021cites this paper
• Impact of delayed graft function on clinical outcomes in highly sensitized patients after deceased-donor kidney transplantation

  2021cites this paper
• Cancer Treatment-Related Lung Injury

  2019cites this paper
• Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.

  2019cites this paper
• Desensitisation strategies in high-risk children before kidney transplantation

  2018cites this paper
• Desensitization: Overcoming the Immunologic Barriers to Transplantation

  2017cites this paper
• Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection

  2017cites this paper